Upcoming milestones

The following list, while not definitive, represents a significant portion of later-stage milestones anticipated by biotechnology companies over the next six to nine months. The criteria for selection were probable completion of Phase II studies or later milestones, including regulatory approvals. If some company milestones have been overlooked, please fax the pertinent information to 415/595-5589 for use in a supplemental table in a future edition of BioCentury.

Advanced Polymer Tretinoin Acne Phase III finished, file NDA end 94
  ProZone Sunscreen Phase III finished, file NDA end 94
Agouron AG 337 Cancer Finish Phase II mid-95
  AG 1343 HIV Finish Phase II mid-95
Athena Diastat Acute repetitive seizures Finish 2d Phase III by May 1995
  Zanaflex Spasticity Awaiting U.S. and Canada approvals
BioChem Pharma 3TC AIDS

Present Phase II/III data 4Q94

Wellcome decides on exercising option 4Q94

Glaxo to file NDA by end 94
Lamivudine Hepatitis B Present Phase II data late Nov. 94
BioCryst BCX-34 Cutaneous T cell lymphoma Phase II start/end 1994, present data at ASCO in spring 95